Literature DB >> 6602845

A novel cell surface antigen (T305) found in increased frequency on acute leukemia cells and in autoimmune disease states.

R I Fox, M Hueniken, S Fong, S Behar, I Royston, S K Singhal, L Thompson.   

Abstract

Monoclonal antibody T305, prepared by immunizing mice with the T-ALL derived cell line RPMI-8402, immunoprecipitates a single chain glycoprotein with m.w. 160,000 daltons (under reducing conditions) or 180,000 daltons (under nonreducing conditions). In immunofluorescence assays, antibody T305 reacted with a subpopulation of T cells in normal blood (22 +/- 6%), thymus (28 +/- 11%), and lymph node (24 +/- 6%). Increased frequency of T cells reactive with antibody T305 was found in peripheral blood of patients with infectious mononucleosis (greater than 80%), graft-vs-host disease after bone marrow transplantation (65 +/- 11%), acquired immunodeficiency syndrome (53 +/- 12%). The T cells in synovial fluid of patients with rheumatoid arthritis had increased frequency of antibody T305 reactive cells (59 +/- 8%) as compared to their peripheral blood (18 +/- 7%). Two color immunofluorescent studies demonstrated that the T305+ T cells predominantly co-stained with antibody Leu 2a (suppressor/cytotoxic subset) in both normals and disease state blood. After cell sorting to obtain T305+ and T305- subpopulations, we demonstrated that a) natural killer and antibody-dependent cellular cytotoxicity activity in normal blood was in the T305+ but not T305- T cells; b) cytotoxic T cells induced by mixed lymphocyte reaction were predominantly T305+; c) T305- T cells could be induced in vitro to express T305 antigen by mitogens or allogeneic B cells; d) the DNA content of T305+ and T305- T cells in normal blood was similar (greater 95% of cells with G0/G1 level); e) after mitogen stimulation, T305 antigen induction on previously T305- cells occurs before S-phase; and f) significantly more [3H]-thymidine after mitogen stimulation was incorporated by originally T305- cells than by originally T305+ cells (p less than 0.001). The T305 antigen was not restricted to T cells because it was also found on myeloid precursors in bone marrow but was not present on polymorphonuclear leukocytes, red blood cells, platelets, muscle, liver, skin, kidney, lung, or brain. Antibody T305 was found on 24/25 cases of acute leukemia (6 T-ALL, 10/11 cALL, 7 AML, and 1 AMOL) but not on 18 cases of chronic leukemia (B-CLL, T-CLL, null CLL, CML). The importance of the T305 antigen is that it is present on a high number of T cells in certain autoimmune diseases and on virtually all acute leukemia cells. Its distribution on immature and in vitro activated cells suggests that it may represent a receptor for signals related to cellular replication or differentiation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602845

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Expression of a gp33/27,000 MW activation inducer molecule (AIM) on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies.

Authors:  P Sánchez-Mateos; M Cebrián; A Acevedo; M López-Botet; M O De Landázuri; F Sánchez-Madrid
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

2.  Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation.

Authors:  M E Hemler; D Glass; J S Coblyn; J G Jacobson
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

3.  Unraveling function and diversity of bacterial lectins in the human microbiome.

Authors:  Louis J Cohen; Sean F Brady; Sun M Han; Pearson Lau; Daniela Guisado; Yupu Liang; Toshiki G Nakashige; Thamina Ali; David Chiang; Adeeb Rahman
Journal:  Nat Commun       Date:  2022-06-03       Impact factor: 17.694

4.  GCNT1-Mediated O-Glycosylation of the Sialomucin CD43 Is a Sensitive Indicator of Notch Signaling in Activated T Cells.

Authors:  Eric Perkey; Dave Maurice De Sousa; Léolène Carrington; Jooho Chung; Alexander Dils; David Granadier; Ute Koch; Freddy Radtke; Burkhard Ludewig; Bruce R Blazar; Christian W Siebel; Todd V Brennan; Jeffrey Nolz; Nathalie Labrecque; Ivan Maillard
Journal:  J Immunol       Date:  2020-02-14       Impact factor: 5.422

5.  Monoclonal antibodies to leucosialin (CD43) induce homotypic aggregation of the human mast cell line HMC-1: characterization of leucosialin on HMC-1 cells.

Authors:  S Weber; B Ruh; E Dippel; B M Czarnetzki
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

6.  Differential epitope expression of Ly-48 (mouse leukosialin).

Authors:  C M Baecher-Allan; J D Kemp; K S Dorfman; R K Barth; J G Frelinger
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

7.  Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes.

Authors:  M Cebrián; E Yagüe; M Rincón; M López-Botet; M O de Landázuri; F Sánchez-Madrid
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

8.  Altered O-glycan synthesis in lymphocytes from patients with Wiskott-Aldrich syndrome.

Authors:  F Piller; F Le Deist; K I Weinberg; R Parkman; M Fukuda
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

9.  T cell lines characterize events in the pathogenesis of the Wiskott-Aldrich syndrome.

Authors:  I J Molina; D M Kenney; F S Rosen; E Remold-O'Donnell
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

10.  Human thymic epithelial cells express an endogenous lectin, galectin-1, which binds to core 2 O-glycans on thymocytes and T lymphoblastoid cells.

Authors:  L G Baum; M Pang; N L Perillo; T Wu; A Delegeane; C H Uittenbogaart; M Fukuda; J J Seilhamer
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.